How many drugs treat Gonorrhea of rectum?

Drug Landscape tracks 10 marketed treatments for Gonorrhea of rectum (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gonorrhea-of-rectum.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gonorrhea of rectum — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gonorrhea of rectum (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gonorrhea of rectum, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Gonorrhea of rectum
Pfizer · 3 drugs in Gonorrhea of rectum
GSK · 2 drugs in Gonorrhea of rectum
Astellas Pharma · 1 drug in Gonorrhea of rectum
Bristol-Myers Squibb · 1 drug in Gonorrhea of rectum
Bulovka Hospital · 1 drug in Gonorrhea of rectum
Centre Hospitalier Universitaire Vaudois · 1 drug in Gonorrhea of rectum
Generic (originally Abbott/Lilly) · 1 drug in Gonorrhea of rectum
Generic (originally Pfizer) · 1 drug in Gonorrhea of rectum
Generic (originally Roche) · 1 drug in Gonorrhea of rectum
Johnson And Johnson · 1 drug in Gonorrhea of rectum
Les Laboratoires des Médicaments Stériles · 1 drug in Gonorrhea of rectum

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gonorrhea of rectum:

Cite this brief

Drug Landscape (2026). Gonorrhea of rectum — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gonorrhea-of-rectum. Accessed 2026-06-10.

Gonorrhea of rectum full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing